Phase 2 Prostate Cancer Trial, Recruiting NCT07073794 Sponsor: Mayo Clinic Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT07073794
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must be a Black or African American man with prostate cancer that is locally advanced, high risk, has come back (based on a PSA blood test), or has spread to other parts of the body
  • You must currently be receiving, or be about to start, one of the specific treatments listed in this trial — these include hormone therapy injections (leuprolide or degarelix), chemotherapy (cabazitaxel), immunotherapy (pembrolizumab), or bone-strengthening treatments (zoledronic acid or denosumab), and at least one of these must be given by a nurse who comes to your home
  • Your treatment must be an approved or officially recommended standard treatment for your type of prostate cancer
  • You are expected to continue your current treatment for at least 18 weeks after joining (if on chemotherapy or immunotherapy) or at least 24 weeks (for all other treatments)
  • You must live within the area served by the home health supplier for this trial
  • You must be well enough to carry out most daily activities (your doctor will assess this using a standard health scale)
  • You must be willing and able to follow the study plan, including completing questionnaires (with help if needed)
  • You must be willing to follow birth control requirements if you are able to father children
  • You must be able to give written consent to participate

Who may not be able to join:

  • You are currently taking part in another clinical trial that involves a treatment for your cancer
  • You are currently staying in hospital as an inpatient (unless you are enrolled in a specific "Advanced Care at Home" programme)
  • You have other serious ongoing health conditions that your doctor believes would make it unsafe or unsuitable for you to take part
  • You have uncontrolled health problems such as an active infection, serious heart failure, unstable chest pain, an irregular heartbeat, a heart attack within the last 6 months, a wound that is not healing, or a mental health or personal situation that would make it hard to follow the study requirements
  • You had a severe infection — including hospitalisation due to an infection, or a suspected or confirmed COVID-19 infection — within the 4 weeks before joining
  • You are expected to need major surgery at any point during the trial (note: radiation therapy during the trial is allowed)
  • You did not pass the home safety and social stability screening required before receiving treatment at home
  • You previously received at-home treatment as part of another trial run by the same research group (CCBW) — though if you joined such a trial but never actually started home treatment, you may still be eligible (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Roxana S. Dronca, MD, Mayo Clinic

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
27 August 2025
Est. completion
27 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient rating of overall cancer care experience - CAHPS; Patient preferences regarding the location of cancer treatment delivery; Incidence of grade 3+ adverse events (AEs); Acute care visits, emergency room visits, and hospitalizations; Avoidable acute care visits, emergency room visits and hospitalizations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov